In in vitro experiments with strong clinical implications, all four types of CAR-T cells showed better performance (i.e., higher avidity, enhanced cytotoxicity against AML, and a stronger production of proinflammatory cytokines such as IFN-γ and IL-2) as compared to single-targeting CAR-T cells. Here, IFNG is linked to acute myeloid leukemia.